Abstract: Provided herein are compounds that inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.

Abstract: A loading platform for a wheeled vehicle. The loading platform comprises a frame extending along a longitudinal axis. The frame comprises an elongated central shell having two spaced-apart elongated beams with an upper end and an elongated central plate secured to and connecting the upper ends of the spaced-apart elongated beams. The frame also comprises cross bracing assemblies extending on opposed sides of the elongated central shell, each one of the cross bracing assemblies including a plurality of intersecting bracing plates secured at a proximal end to a respective one of the elongated beams of the central shell.

Abstract: A loading platform for a wheeled vehicle. The loading platform comprises a frame extending along a longitudinal axis. The frame comprises an elongated central shell having two spaced-apart elongated beams with an upper end and an elongated central plate secured to and connecting the upper ends of the spaced-apart elongated beams. The frame also comprises cross bracing assemblies extending on opposed sides of the elongated central shell, each one of the cross bracing assemblies including a plurality of intersecting bracing plates secured at a proximal end to a respective one of the elongated beams of the central shell.

Abstract: The present invention is directed to processes for preparing a pyridyl piperidine compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.

Abstract: Nonmetallic, chiral organic catalysts are used to catalyze the 1,4-hydride reduction of an ?,?-unsaturated carbonyl compound. The ?,?-unsaturated carbonyl compound may be an aldehyde or cyclic ketone, and the hydride donor may be a dihydropyridine. The reaction is enantioselective, and proceeds with a variety of hydride donors, catalysts, and substrates. The invention also provides compositions effective in carrying out the 1,4-hydride addition of ?,?-unsaturated carbonyl compounds.

Abstract: Nonmetallic, chiral organic catalysts are used to catalyze the 1,4-hydride reduction of an ?,?-unsaturated carbonyl compound. The ?,?-unsaturated carbonyl compound may be an aldehyde or cyclic ketone, and the hydride donor may be a dihydropyridine. The reaction is enantioselective, and proceeds with a variety of hydride donors, catalysts, and substrates. The invention also provides compositions effective in carrying out the 1,4-hydride addition of ?,?-unsaturated carbonyl compounds.

Abstract: Nonmetallic, chiral organic catalysts are used to catalyze the 1,4-hydride reduction of an ?,?-unsaturated carbonyl compound. The ?,?-unsaturated carbonyl compound may be an aldehyde or cyclic ketone, and the hydride donor may be a dihydropyridine. The reaction is enantioselective, and proceeds with a variety of hydride donors, catalysts, and substrates. The invention also provides compositions effective in carrying out the 1,4-hydride addition of ?,?-unsaturated carbonyl compounds.